Champions Oncology (CSBR) Cash & Equivalents (2010 - 2026)

Champions Oncology's Cash & Equivalents history runs 17 years deep, the most recent figure standing at $7.1 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 122.58% year-over-year to $7.1 million; the TTM figure through Jan 2026 stood at $7.1 million (up 122.58% YoY), while the FY2025 annual figure was $9.8 million, up 273.76% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $7.1 million, down from $8.5 million in the prior quarter.
• The five-year high for Cash & Equivalents was $11.6 million in Q1 2023, with the low at $2.6 million in Q2 2024.
• The 5-year median for Cash & Equivalents is $8.1 million (2022), against an average of $7.1 million.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents plunged 74.13% in 2024, then jumped 273.76% in 2025.
• Champions Oncology's Cash & Equivalents stood at $10.8 million in 2022, then slumped by 49.08% to $5.5 million in 2023, then plunged by 50.05% to $2.8 million in 2024, then soared by 209.22% to $8.5 million in 2025, then retreated by 16.31% to $7.1 million in 2026.
• Business Quant data shows CSBR's Cash & Equivalents at $7.1 million in Q1 2026, $8.5 million in Q4 2025, and $10.3 million in Q3 2025.